MLL1 Inhibitor Compounds Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective selective inhibitors for Mixed Lineage Leukemia 1 (MLL1), a key driver in various leukemias and solid tumors, necessitating the development of compounds that can specifically target and inhibit MLL1 to treat associated diseases.
Innovation Solution
Development of novel compounds of Formula (I) and their pharmaceutical compositions, which include enantiomers, enantiomeric mixtures, and pharmaceutically acceptable salts, designed to inhibit MLL1 by targeting specific structural features, thereby treating or preventing conditions mediated by MLL1 overexpression or undesired upregulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of leukemias and solid tumors is provided, but effective selective inhibition of MLL1 is not achieved
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular structures of compounds to optimize their binding affinity and selectivity for MLL1. By modifying chemical parameters such as substituent groups, molecular weight, and structural configuration, the invention achieves compounds that selectively inhibit MLL1 with IC50 values in the nanomolar range, resolving the contradiction between selectivity and therapeutic effectiveness.
Solution Approach 2:
The patent applies local quality by designing compounds with specific functional groups and structural features that target particular regions of the MLL1 protein. The compounds contain specific pharmacophoric elements that interact with key amino acid residues in the MLL1 binding pocket, enabling selective inhibition while maintaining high therapeutic effectiveness against MLL1-driven leukemias and solid tumors.
2Productivity
If MLL1 is inhibited, then leukemias and solid tumors are treated, but selective inhibitors are still needed
Solution Approach 1:
The patent uses intermediary compounds that mediate between the therapeutic goal of MLL1 inhibition and the requirement for selectivity. These small molecule inhibitors act as intermediaries that specifically bind to MLL1 without significantly affecting other histone methyltransferases, thereby achieving both high therapeutic effectiveness and selectivity through carefully designed molecular structures with optimal binding characteristics.
3Reliability
If compounds of Formula (I) are developed, then MLL1 inhibition is achieved, but complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the complex MLL1 inhibitor into distinct modular components or fragments. The compounds of Formula (I) can be viewed as assembled from separate structural units that each contribute specific binding interactions, allowing for systematic optimization of inhibition efficacy while managing molecular complexity through modular design principles.
Data Source
AI summary
The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL).